NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEXXEL is a fixed-dose combination tablet containing enalapril maleate (ACE inhibitor) and felodipine (calcium channel blocker) in extended-release formulation. It is indicated for hypertension management in patients who require dual antihypertensive therapy. This combination leverages complementary mechanisms to achieve additive blood pressure reduction.
LOE Approaching
With LOE approaching, the brand team is likely focused on lifecycle management and preparing for generic erosion; headcount and investment are expected to decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LEXXEL offers exposure to cardiovascular pharmacotherapy and managed care navigation in a mature market segment. Career progression is likely limited by the product's LOE trajectory; professionals should expect focus on market defense, generic transitions, and cost management rather than expansion.
Brand ManagerField Sales Representative
Worked on LEXXEL at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.